Valve-in-Valve: High or Low Implantation for Better Outcomes?

Original Title: Transcatheter Replacement of Failed Bioprosthetic Valve. Large Multicenter Assessment of the Effect of Implantation Depth on Hemodynamics after Aortic Valve-in Valve.

Reference: Matheus Simonato, et al. Circ. Cardiovasc. Interv 2016;9:e003651

 

Courtesy of Dr. Carlos Fava.

 

valve_in_valveAt present, most patients undergoing surgical valve replacement receive a bioprosthetic valve, which lasts from 10 to 15 years. However, when it starts failing, reoperation is a high risk.

Transcatheter valve implantation inside a failed surgical bioprosthetic valve (V-in-V) could eventually solve this problem, but its evolution and exact implantation depth continues to raise questions.

The study analyzed 292 high risk consecutive patients form the International V-in-V (VIVID) registry.

The purpose of this study was to determine optimal implantation depth for the best hemodynamic outcome, defined as <20 mmHg gradient.

Mean age was 78.9 years with more than 90% patients with symptomatic dyspnea in FC III-IV. Bioprosthetic valves had failed approximately 10 after procedure, caused by:

  • stenosis, 40%
  • mixed factors, 35%
  • regurgitation, 25%

From the total number of patients, 157 received the CoreValve and 135 the Sapiens XT.

High implantation depth was associated to lower rates of post implantation elevated gradients compared to low implantation depth, and this was true for both valves:

CoreValve Evolut

  • High implantation depth 15%
  • Low implantation depth 34.2%

p=0.03

Sapiens XT

  • High implantation 18.5%
  • Low implantation 43.5%

p=0.03

Implantation depth was a strong predictor of post implantation gradient.

 

Conclusion

High implantation, both for CoreValve and Sapiens XT ─ inside a failed surgical valve ─ is a strong independent predictor of satisfactory hemodynamic outcomes.

 

Editorial Comment

V-in-V is a significantly less invasive strategy that solves stenosis or failure of bioprosthetic surgical valves.

To meet its increasing demand and optimize results requires that we master this implantation technique.

 

Courtesy of Dr. Carlos Fava. Favaloro Foundation, Buenos Aires, Argentina.

 

We value your opinion. You are more than welcome to leave your comments, thoughts, question or any ideas here below.

More articles by this author

Measuring Post-TAVI Gradients and Their Implications: Are Invasive and Echocardiographic Assessments Comparable?

Transcatheter aortic valve implantation (TAVI) is considered the treatment of choice for a significant proportion of patients with symptomatic aortic stenosis. Outcomes have improved...

Percutaneous Tricuspid Valve Replacement with Lux-Valve

Tricuspid regurgitation (TR) is a condition associated with poor quality of life, frequent hospitalizations due to heart failure, and increased mortality, even under optimal...

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Pretreatment with DAPT in Acute Coronary Syndrome: An Ongoing Debate?

In acute coronary syndrome (ACS) dual antiplatelet therapy (DAPT) has become a fundamental pillar after percutaneous coronary intervention (PCI), preventing stent thrombosis and acute...

Measuring Post-TAVI Gradients and Their Implications: Are Invasive and Echocardiographic Assessments Comparable?

Transcatheter aortic valve implantation (TAVI) is considered the treatment of choice for a significant proportion of patients with symptomatic aortic stenosis. Outcomes have improved...

Another Blow for Intra-Aortic Balloon Pumo Counterpulsation? Randomized Study on Its Use in Chronic Heart Failure Progressing to Cardiogenic Shock

Cardiogenic shock (CS) remains a condition with extremely high mortality (around 50%). While most therapies for this pathology have been studied in CS secondary...